Fixed combination lisinopril plus hydrochlorothiazide in the treatment of essential arterial hypertension: An opened, multi-centre, prospective clinical trial

被引：5

作者：

Gerc, Vjekoslav ^{[2
]}

Begovic, Begler ^{[1
]}

Vehabovic, Midhat

Voronkov, Leonid Georgievich ^{[3
]}

Vataman, Eleonora ^{[4
]}

Muzic, Ljiljana ^{[5
]}

Buksa, Marko ^{[2
]}

Kusljugic, Zumreta ^{[6
]}

Ilyash, Maria Grigorevna ^{[3
]}

Tchelujko, Vera Iosifovna ^{[7
]}

Dyaduk, Alexander Ivanovich ^{[8
]}

Andrievskaja, Svetlana Alekseevna ^{[9
]}

Bagrij, Andrey Eduardovich

Michaylovna, Ena Larisa ^{[10
]}

Lazarevic, Aleksandar ^{[11
]}

Knezevic, Bozidarka ^{[12
]}

Hima, Faik ^{[13
]}

机构：

[1] Univ Sarajevo, Ctr Clin, Inst Clin Pharmacol, Sarajevo 71000, Bosnia & Herceg

[2] Univ Sarajevo, Ctr Clin, Clin Heart Dis & Rheumatism, Sarajevo 71000, Bosnia & Herceg

[3] Ukraine Acad Med Sci, Inst Cardiol, UA-03126 Kiev, Ukraine

[4] Sci Dept Med, Kishinev 2000, Moldova

[5] Clin Ctr Montenegro, Clin Heart Dis, Podgorica 81000, Montenegro

[6] Univ Clin Ctr Tuzla, Dept Cardiol, Tuzla 75000, Bosnia & Herceg

[7] City Hosp, UA-61000 Kharkov, Ukraine

[8] City Hosp, UA-83000 Donetsk, Ukraine

[9] Reg Cardiol Clin, UA-65000 Odessa, Ukraine

[10] Ukraine Acad Med Sci, Inst Gerontol, UA-03126 Kiev, Ukraine

[11] Ctr Clin, Clin Internal Dis, Banja Luka 51000, Bosnia & Herceg

[12] Clin Ctr Montenegro, Clin Heart Dis, Podgorica 81000, Montenegro

[13] Internal Clin UCC Pristina, Pristina 10000, Kosovo, Serbia

来源：

BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES | 2007年 / 7卷 / 04期

关键词：

essential hypertension; lisinopril; hydrochlorthiazide;

D O I：

10.17305/bjbms.2007.3031

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The aim of this trial was to examine the efficacy and safety of antihypertensive fixed combination lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd) in the treatment of essential arterial hypertension, In our trial we included 297 patients, aged 54,65 +/- 9,6 years, with treated or untreated hypertension and with high risk of cardiac events, in an opened trial of therapy based oil lisinopril Plus hydrochlorothiazide. Upon the examination by physicians, patients were divided into three groups in accordance with European Society of Cardiology guidelines for the management of arterial hypertension. Patients from five European countries were followed up for a period of 12 weeks. Duration of treatment was 12 weeks. We adjusted daily doses of lisinopril Plus hydrochlorothiazide after every clinical examination and recorded adverse effects of drugs. After 12 weeks of treatment, 288 patients (96%) were evaluated for efficacy, tolerability and safety. In almost 81.5% patients with mild, moderate and severe hypertension, we recorded a reduction in blood pressure to approximately normal values SBP and DBP (140/90 mmHg). Drug-related side-effects occurred in 11 patients (3,66%). The most commonly reported adverse effects associated with lisinopril plus hydrochlorothiazide were cough (5) and dry mouth (5). This research has proved good efficacy of fixed combination lisinopril Plus hydrochlorothiazide with more than 97% patients. Based on subjective estimation by patients: this drug improved quality of life in all cases.

引用

页码：377 / 382

页数：6